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BayesCCE: a Bayesian framework for
estimating cell-type composition from DNA
methylation without the need for methylation
reference
Elior Rahmani1 , Regev Schweiger2, Liat Shenhav1, Theodora Wingert3, Ira Hofer3, Eilon Gabel3,
Eleazar Eskin1,4 and Eran Halperin1,3,4*
Abstract
We introduce a Bayesian semi-supervised method for estimating cell counts from DNA methylation by leveraging an
easily obtainable prior knowledge on the cell-type composition distribution of the studied tissue. We show
mathematically and empirically that alternative methods which attempt to infer cell counts without methylation
reference only capture linear combinations of cell counts rather than provide one component per cell type. Our
approach allows the construction of components such that each component corresponds to a single cell type, and
provides a new opportunity to investigate cell compositions in genomic studies of tissues for which it was not
possible before.
Keywords: DNA methylation, Cell-type composition, Tissue heterogeneity, Cell counts, Bayesian model, Epigenetics,
Epigenome-wide association studies
Background
DNA methylation status has become a prominent epige-
netic marker in genomic studies, and genome-wide DNA
methylation data have become ubiquitous in the last few
years. Numerous recent studies provide evidence for the
role of DNA methylation in cellular processes and in dis-
ease (e.g., in multiple sclerosis [1], schizophrenia [2], and
type 2 diabetes [3]). Thus, DNA methylation status holds
great potential for better understanding the role of epi-
genetics, potentially leading to better clinical tools for
diagnosing and treating patients.
In a typical DNA methylation study, we obtain a large
matrix in which each entry corresponds to a methylation
level (a number between 0 and 1) at a specific genomic
position for a specific individual. This level is the fraction
of the probed DNA molecules that were found to have
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an additional methyl group at the specific position for the
specific individual. Essentially, these methylation levels
represent, for each individual and for each site, the prob-
ability of a given DNA molecule to be methylated. While
simple in principle, methylation data are typically com-
plicated owing to various biological and non-biological
sources of variation. Particularly, methylation patterns are
known to differ between different tissues and between dif-
ferent cell types. As a result, when methylation levels are
collected from a complex tissue (e.g., blood), the observed
methylation levels collected from an individual reflect a
mixture of its methylation signals coming from different
cell types, weighted according to mixing proportions that
depend on the individual’s cell-type composition. Thus,
it is challenging to interpret methylation signals coming
from heterogeneous sources.
One notable challenge in working with heterogeneous
methylation levels has been highlighted in the context of
epigenome-wide association studies (EWAS), where data
are typically collected from heterogeneous samples. In
such studies, we typically search for rows of the methyla-
tion matrix (each corresponding to one genomic position)
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
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that are significantly correlated with a phenotype of inter-
est across the samples in the data. In this case, unless
accounted for, correlation of the phenotype of interest
with the cell-type composition of the samples may lead
to numerous spurious associations and potentially mask
true signal [4]. In addition to its importance for a correct
statistical analysis, knowledge of the cell-type composi-
tion may provide novel biological insights by studying cell
compositions across populations.
In principle, one can use high-resolution cell counting
for obtaining knowledge about the cell composition of
the samples in a study. However, unfortunately, such cell
counting for a large cohort may be costly and often logis-
tically impractical (e.g., in some tissues, such as blood,
reliable cell counting can be obtained from fresh sam-
ples only). Due to the pressing need to overcome this
limitation, development of computational methods for
estimating cell-type composition from methylation data
has become a key interest in epigenetic studies. Sev-
eral such methods have been suggested in the past few
years [5–10], some of which aim at explicitly estimating
cell-type composition, while others aim at a more spe-
cific goal of correcting methylation data for the potential
cell-type composition confounder in association studies.
These methods take either a supervised approach, in
which reference data of methylation patterns from sorted
cells (methylomes) are obtained and used for predict-
ing cell compositions [5], or an unsupervised approach
(reference-free) [6–10].
The main advantage of the reference-based method
is that it provides direct (absolute) estimates of the
cell counts, whereas, as we demonstrate here, current
reference-free methods are only capable of inferring com-
ponents that capture linear combinations of the cell
counts. Yet, the reference-based method can only be
applied when relevant reference data exist. Currently, ref-
erence data only exist for the blood [11], breast [12], and
brain [13], for a small number of individuals (e.g., six sam-
ples in the blood reference [11]).Moreover, the individuals
in most available data sets do not match the reference
individuals in their methylation-altering factors, such as
age [14], gender [15, 16], and genetics [17]. This problem
was recently highlighted in a study in which the authors
showed that available blood reference collected from
adults failed to estimate cell proportions of newborns [18].
Furthermore, in a recent work, we showed evidence from
multiple data sets that a reference-free approach can pro-
vide substantially better correction for cell composition
when compared with the reference-based method [19]. It
is therefore often the case that unsupervised methods are
either the only option or a better option for the analysis of
EWAS.
As opposed to the reference-based approach, although
can be applied for any tissue in principle, the reference-
free methods do not provide direct estimates of the
cell-type proportions. Previously proposed reference-free
methods allow us to infer a set of components, or general
axes, which were shown to compose linear combinations
of the cell-type composition [8, 9]. Another more recent
reference-free method was designed to infer cell-type
proportions; however, as we show here, it only provides
components that compose linear combinations of the cell-
type composition rather than direct estimates [10]. Unlike
cell proportions, while linearly correlated components are
useful in linear analyses such as linear regression, they
cannot be used in any nonlinear downstream analysis or
for studying individual cell types (e.g., studying alterations
in cell composition across conditions or populations). Cell
proportions may provide novel biological insights and
contribute to our understanding of disease biology, and
we therefore need targeted methods that are practical
and low in cost for estimating cell counts.
In an attempt to address the limitations of previous
reference-free methods and to provide cell count esti-
mates rather than linear combinations of the cell counts,
we propose an alternative Bayesian strategy that uti-
lizes prior knowledge about the cell-type composition
of the studied tissue. We present a semi-supervised
method, BayesCCE (Bayesian Cell Count Estimation),
which encodes experimentally obtained cell count infor-
mation as a prior on the distribution of the cell-type com-
position in the data. As we demonstrate here, the required
prior is substantially easier to obtain compared with stan-
dard reference data from sorted cells.We can estimate this
prior from general cell counts collected in previous stud-
ies, without the need for corresponding methylation data
or any other genomic data.
We evaluate our method using four large methylation
data sets and simulated data and show that our method
produces a set of components that can be used as cell
count estimates. We observe that each component of
BayesCCE can be regarded as corresponding to scaled
values of a single cell type (i.e., high absolute correlation
with one cell type, but not necessarily good estimates in
absolute terms). We find that BayesCCE provides a sub-
stantial improvement in correlation with the cell counts
over existing reference-free methods (in some cases a
50% improvement). We also consider the case where both
methylation and cell count information are available for
a small subset of the individuals in the sample, or for a
group of individuals from external data. Notably, existing
reference-based and reference-free methods for cell-type
estimation completely ignore this potential information.
In contrast, our method is flexible and allows to incor-
porate such information. Specifically, we show that our
proposed Bayesian model can leverage such additional
information for imputing missing cell counts in absolute
terms. Testing this scenario on both real and simulated
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data, we find that measuring cell counts for a small group
of samples (a couple of dozens) can lead to a further
significant increase in the correlation of BayesCCE’s com-
ponents with the cell counts.
Results
Benchmarking existing reference-free methods for
capturing cell-type composition
We first demonstrate that existing reference-free meth-
ods can infer components that are correlated with the
tissue composition of DNA methylation data collected
from heterogeneous sources. For this experiment, as well
as for the rest of the experiments in this paper, we used
four large publicly available whole-bloodmethylation data
sets: a data set by Hannum et al. [20] (n = 650), a
data set by Liu et al. [21] (n = 658), and two data sets
by Hannon et al. [22] (n = 638 and n = 665; denote
Hannon et al. I and Hannon et al. II, respectively). In addi-
tion, we simulated data based on a reference data set of
methylation levels from sorted leukocyte cells [11] (see
the “Methods” section). While cell counts were known
for each sample in the simulated data, cell counts were
not available for the real data sets. We therefore esti-
mated the cell-type proportions of six major blood cell
types (granulocytes, monocytes, and four subtypes of lym-
phocytes: CD4+, CD8+, B cells, and natural killer cells)
based on a reference-based method [5], which was shown
to reasonably estimate leukocyte cell proportions from
whole-blood methylation data collected from adult indi-
viduals [18, 23, 24]. Due to the absence of large publicly
available data sets with measured cell counts, these esti-
mates were considered as the ground truth for evaluating
the performance of the different methods.
For benchmarking performance of existing methods,
we considered three reference-free methods, all of which
were shown to generate components that capture cell-
type composition information from methylation: ReFAC-
Tor [8], non-negative matrix factorization (NNMF) [9],
and MeDeCom [10]. Although the reference-free meth-
ods can potentially allow the detection of more cell types
than the set of predefined cell types in the reference-
based approach, we evaluated six components of each
of the reference-free methods—six being the number of
estimated cell types composing the ground truth. We
found all methods to capture a large portion of the
cell composition information in all data sets; particu-
larly, we observed that ReFACTor performed consider-
ably better than NNMF and MeDeCom in all occasions
(Additional file 1: Figure S1).
In spite of the fact that all three methods can capture a
large portion of the cell composition variation, each com-
ponent provided by these methods is a linear combination
of the cell types in the data rather than an estimate of the
proportions of a single cell type. As a result, as we show
next, in general, these methods perform poorly when their
components are considered as estimates of cell type pro-
portions. ReFACTor was not designed for estimating cell
proportions but rather for providing orthogonal princi-
pal components of the data that together capture variation
in cell compositions. In contrast, NNMF and MeDe-
Com, which extends the underlyingmodel in NNMF, were
designed to provide estimates of cell type proportions. In
addition to empirical support from the data, as we report
next, we also provide a mathematical proof for the non-
identifiability nature of the NMMF model, which drives
solutions towards undesired linear combinations of cell-
type proportions rather than direct estimates of cell-type
proportions (see the “Methods” section).
BayesCCE: a Bayesian semi-supervised approach for
capturing cell-type composition
Every method that has been developed so far for capturing
cell composition signal frommethylation can be classified
as either reference-based, wherein a reference of methy-
lation patterns of sorted cells is used, or reference-free,
wherein cell composition information is inferred in an
unsupervised manner. Our proposed method, BayesCCE,
combines elements from the underlying models of pre-
vious reference-free methods with further assumptions.
BayesCCE does not use standard reference data of sorted
methylation levels, but rather it leverages relatively weak
prior information about the distribution of cell-type com-
position in the studied tissue. This allows BayesCCE
to direct the solution towards the inference of one
component for each cell type that is encoded in the
prior information. BayesCCE is fully described in the
“Methods” section.
In order to evaluate BayesCCE, we obtained prior infor-
mation about the distribution of leukocyte cell-type pro-
portions in blood using high-resolution blood cell counts
that were previously measured in 595 adult individuals
(see the “Methods” section). In concordance with the esti-
mated cell-type proportions used as the ground truth, we
first considered the assumption of six constituting cell
types in blood tissue (k = 6). We applied BayesCCE on
each of the four data sets and evaluated the resulted com-
ponents.We observed that each time BayesCCE produced
a set of six components such that each component was
correlated with one of the cell types, as desired (Fig. 1
and Additional file 1: Tables S1 and S2). Specifically, we
found the mean absolute correlation values across all six
cell types to be 0.58, 0.63, 0.45, and 0.45 in the Hannum
et al., Liu et al., Hannon et al. I, and Hannon et al. II
data sets, respectively. We note, however, that the assign-
ment of components into corresponding cell types could
not be automatically determined by BayesCCE. In addi-
tion, in general, the BayesCCE components were not in
the right scale of their corresponding cell types (i.e., each
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Fig. 1 BayesCCE captures cell-type proportions in four data sets under the assumption of six constituting cell types in the blood (k = 6):
granulocytes, monocytes, and four subtypes of lymphocytes (CD4+, CD8+, B cells, and NK cells). The BayesCCE estimated components were linearly
transformed to match their corresponding cell types in scale (see the “Methods” section). For convenience of visualization, we only plot the results
of 100 randomly selected samples for each data set
component represented the proportions of one cell type
up to a multiplicative constant and addition of a con-
stant). These symptoms are expected due to the nature
of the prior information used by BayesCCE. For more
details about the assignment of components into cell
types and evaluation measurements, see the “Methods”
section.
We next considered a simplifying assumption of only
three constituting cell types in blood tissue (k = 3):
granulocytes, lymphocytes, and monocytes. We applied
BayesCCE on each of the four data sets and observed high
correlations between the estimated components of gran-
ulocytes and the granulocyte levels (r ≥ 0.91 in all data
sets) and between the estimated components of lympho-
cytes and the lymphocyte levels (r ≥ 0.87 in all data sets),
yet much lower correlations for monocytes (r ≤ 0.27
in all data sets; Additional file 1: Figure S2 and Tables
S1 and S2). We note that poor performance in capturing
some cell type may be partially derived by inaccuracies
introduced by the reference-based estimates, which are
used as the ground truth in our experiments. Notably,
three recent studies, which consisted of samples for which
both methylation levels and cell count measurements
were available, demonstrated that while the reference-
based estimates of the overall lymphocyte and granulocyte
levels were found to be highly correlated with the true
levels, the accuracy of estimated monocytes was found to
be substantially lower [8, 18, 25]. This may explain the
low correlations we report for monocytes in our experi-
ments. Low correlations with some of the cell types may
be driven by various reasons, such as utilizing inappropri-
ate reference or failing to perform a good feature selection.
We later provide a more detailed discussion about these
issues.
For assessing the performance of BayesCCE in light
of previous reference-free methods, we sub-sampled the
data and generated ten data sets of 300 randomly selected
samples from each one of the four data sets. In addi-
tion, we simulated ten data sets of similar size (n = 300;
see the “Methods” section). Figure 2 demonstrates a sig-
nificant and substantial improvement in performance for
BayesCCE upon existing methods under the assumption
of six constituting cell types (k = 6). Repeating the same
set of experiments while assuming three constituting cell
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Fig. 2 The performance of existing reference-free methods and BayesCCE under the assumption of six constituting cell types in blood (k = 6):
granulocytes, monocytes, and four subtypes of lymphocytes (CD4+, CD8+, B cells, and NK cells). For each method, box plots show for each data set
the performance across ten sub-sampled data sets (n = 300), with the median indicated by a horizontal line. For each of the methods, ReFACTor,
NNMF, MeDeCom, and BayesCCE, we considered a single component per cell type (see the “Methods” section). Additionally, we considered the
scenario of cell count imputation wherein cell counts were known for 5% of the samples (n = 15; BayesCCE imp) and the scenario wherein samples
from external data with both methylation levels and cell counts were used in the analysis (n = 15; BayesCCE imp ext). Top panel: mean absolute
correlation (MAC) across all cell types. Bottom panel: mean absolute error (MAE) across all cell types. For BayesCCE imp and BayesCCE imp ext, the
MAC and MAE values were calculated while excluding the samples with assumed known cell counts
types (k = 3) revealed similar results (Additional file 1:
Figure S3).
BayesCCE impute: cell count imputation
We next considered a scenario in which cell counts are
known for a small subset of the samples in the data. This
problem can be viewed as a problem of imputing missing
cell count values (see “Methods” section). We repeated all
previous experiments, only this time we assumed that cell
counts are known for randomly selected 5% of the samples
in each data set. As opposed to the previous experi-
ments, in which each one of the BayesCCE components
constituted a scaled estimate of the proportions of one
of the cell types, incorporating samples with known cell
counts allowed BayesCCE to produce components that
form absolute estimates of the cell type proportions (i.e.,
not scaled components, but components with low abso-
lute error compared with the true proportions). Moreover,
in contrast to previous experiments, each component was
now automatically assigned to its corresponding cell type.
Under the assumption of six constituting cell types in
blood tissue (k = 6), we observed a substantial improve-
ment of up to 58% in mean absolute correlation values
compared with our previous experiments (Fig. 3 and
Additional file 1: Tables S1 and S2). Specifically, we found
the mean absolute correlation values across all six cell
Rahmani et al. Genome Biology  (2018) 19:141 Page 6 of 18
0 0.2 0.4 0.6 0.8 1
Ref-based
0
0.2
0.4
0.6
0.8
1
B
ay
es
C
C
E
Hannum et al. (n=650)
Gran (r=0.95)
CD4+ (r=0.84)
CD8+ (r=0.59)
B (r=0.9)
NK (r=0.62)
Mono (r=0.36)
0 0.2 0.4 0.6 0.8 1
Ref-based
0
0.2
0.4
0.6
0.8
1
B
ay
es
C
C
E
Liu et al. (n=658)
Gran (r=0.98)
CD4+ (r=0.8)
CD8+ (r=0.65)
B (r=0.6)
NK (r=0.5)
Mono (r=0.46)
0 0.2 0.4 0.6 0.8 1
Ref-based
0
0.2
0.4
0.6
0.8
1
B
ay
es
C
C
E
Hannon et al. I (n=638)
Gran (r=0.95)
CD4+ (r=0.73)
CD8+ (r=0.4)
B (r=0.62)
NK (r=0.33)
Mono (r=0.31)
0 0.2 0.4 0.6 0.8 1
Ref-based
0
0.2
0.4
0.6
0.8
1
B
ay
es
C
C
E
Hannon et al. II (n=665)
Gran (r=0.97)
CD4+ (r=0.74)
CD8+ (r=0.59)
B (r=0.81)
NK (r=0.62)
Mono (r=0.49)
Fig. 3 BayesCCE captures cell-type proportions in four data sets under the assumption of six constituting cell types in blood (k = 6): granulocytes,
monocytes, and four subtypes of lymphocytes (CD4+, CD8+, B cells, and NK cells), and assuming known cell counts for randomly selected 5% of the
samples in the data. All correlations were calculated while excluding the samples with assumed known cell counts. For convenience of visualization,
we only plot the results of 100 randomly selected samples for each data set
types to be 0.71, 0.66, 0.56, and 0.71 in the Hannum et
al., Liu et al., Hannon et al. I, and Hannon et al. II data
sets, respectively. In addition, in contrast to our previous
experiments, inclusion of some cell counts resulted in low
mean absolute error, which reflects a correct scale for the
components. We observed similar results when assum-
ing three constituting cell types (k = 3), providing an
improvement of up to 28% in correlation and a substantial
decrease in absolute errors compared with the previous
experiments (Additional file 1: Figure S4 and Tables S1
and S2).
In the absence of cell counts for a subset of the indi-
viduals in the data, we can incorporate into the analysis
the external data of samples for which both cell counts
and methylation levels (from the same tissue) are avail-
able. We repeated again all previous experiments (k = 3
and k = 6); only this time for each data set, we added
a randomly selected subset of samples from one of the
other data sets (5% of the original sample size) and used
both their methylation levels and cell-type proportions in
the analysis. Specifically, we used randomly selected sam-
ples and corresponding estimates of cell-type proportions
from the Hannon et al. I data set for the experiments in all
three other data sets, and samples from the Hannon et al.
II data set for the experiment with the Hannon et al. I data
set. In order to pool samples from two data sets together,
we considered only the intersection of CpG sites that were
available for analysis in the two data sets. In addition,
unlike in the previous experiments, here, we potentially
introduce new batch effects into the analysis, as in each
experiment the original sample is combined with external
data. We therefore accounted for the new batch informa-
tion by adding it as a new covariate into BayesCCE. As in
the case of known cell counts for a subset of the samples,
we found that the inclusion of external samples with both
methylation and cell counts substantially improved the
performance in terms of correlation and absolute errors
(Additional file 1: Figures S5 and S6 and Tables S1 and S2).
These results clearly show that estimates can be dramati-
cally more accurate given the measured cell counts for as
few as a couple of dozens of samples in the data (or such
samples from external data).
As before, for assessing performance more thoroughly,
we applied BayesCCE on the same sub-sampled data
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sets we used before (n = 300), while assuming known
cell counts for a subset of the samples. In one scenario,
we assumed cell counts are known for 5% of the sam-
ples in each data set (n = 15), and in a second sce-
nario, we included into the analysis methylation levels
and cell-type proportions of 15 samples from external
data. These experiments revealed in most cases a sub-
stantial improvement in correlation over a standard exe-
cution of BayesCCE (i.e., without inclusion of cell counts)
and revealed in all cases a substantial improvement in
the mean absolute error. The results are summarized in
Fig. 2 for the case of six constituting cell types (k = 6)
and in Additional file 1: Figure S3 for the case of three
constituting cell types (k = 3).
We further tested the performance of BayesCCE as
a function of the number of samples for which cell
counts are available. Remarkably, we found that known
cell counts for only a couple of dozens of the samples
are needed in order to achieve the maximal improvement
in performance, including more samples with known cell
counts did not provide a further improvement (Fig. 4).
In addition, we evaluated the performance of BayesCCE
as a function of the sample size. Interestingly, while
performance did not improve by increasing the sample
over a few hundred of samples in the case of unknown
cell counts, we found that knowledge of cell counts
for as few as 15 samples in the data allowed a mono-
tonic improvement in performance in larger sample sizes
(Additional file 1: Figure S7).
Finally, we considered an alternative approach for ver-
ifying the results of BayesCCE. Although our study
aims at estimating cell-type proportions without the
need for reference methylation data, BayesCCE jointly
learns cell-type composition and cell-type-specific mean
methylation levels (methylomes). Hence, as a by-product
of the BayesCCE algorithm, we also obtain cell-type-
specific methylomes across the CpG sites selected by
BayesCCE as part of its feature selection process (see the
“Methods” section). Our experiments found BayesCCE
to provide one component per cell type; however, these
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Fig. 4 Performance of BayesCCE as a function of the number of samples for which cell counts are known, under the assumption of six constituting
cell types in blood (k = 6): granulocytes, monocytes, and four subtypes of lymphocytes (CD4+, CD8+, B cells, and NK cells). Presented are the
medians of the mean absolute correlation values (MAC; in blue) and the medians of the mean absolute error values (MAE; in red) across the six cell
types. Error bars indicate the range of MAC and MAE values across ten different executions for each number of samples with known cell counts. In
every execution, samples with known cell counts were randomly selected, and all MAC and MAE values were calculated while excluding the
samples with assumed known cell counts
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components are not necessarily appropriately scaled,
which implies that estimated cell-type-specific methyla-
tion profiles are also not necessarily calibrated. Never-
theless, in the scenario where cell counts were known
even for a small subset of the individuals in the study,
BayesCCE provided calibrated cell count estimates. In
such cases, we therefore expect BayesCCE to pro-
vide calibrated cell-type-specific methylation profiles.
Using correlation maps, for each of the four whole-
blood methylation data sets we analyzed, we verified
high similarity between the cell-type-specific methylomes
obtained by BayesCCE to those estimated by a reference
methylation data collected from sorted blood cells [11]
(Additional file 1: Figure S8). In spite of an overall high
similarity between these two approaches, the correla-
tion patterns detected by BayesCCE did not perfectly
match those estimated using the reference data. While
this may demonstrate the expected accuracy limitations of
BayesCCE to some extent, we also attribute these imper-
fect matches, at least in part, to inaccuracies introduced
by the reference data set, owing to the fact that it was con-
structed only from a small group of individuals (n = 6),
which do not represent well all the individuals in other
data sets in terms of methylome altering factors such as
age [14], gender [15, 16], and genetics [17].
Robustness of BayesCCE to biases introduced by the cell
composition prior
BayesCCE relies on prior information about the distribu-
tion of the cell-type composition in the studied tissue. In
practice, the available prior information may not always
precisely reflect the cell composition distribution of the
individuals in the study. For instance, in a case/control
study design, cases may demonstrate altered cell compo-
sitions compared with healthy individuals. Therefore, in
this scenario, a prior estimated from a healthy popula-
tion (or a sick population) is expected to deviate from
the actual distribution in the sample. This potential prob-
lem is clearly not limited to case/control studies, but also
applies to studies with quantitative phenotypes, in case
these are correlated with changes in cell composition of
the studied tissue. In principle, we can address this issue
by incorporating several appropriate priors and assigning
different priors to different individuals in the study. How-
ever, in practice, population-specific priors may be hard
to obtain, mainly owing to the fact that numerous known
and unknown factors can affect cell composition.
We revisited our analysis from the previous subsections
in an attempt to assess the robustness of BayesCCE to
non-informative or misspecified priors. A desired behav-
ior would allow BayesCCE to overcome a bias introduced
by a prior which does not accurately represent all the indi-
viduals in the sample. Particularly, we considered three
whole-blood case/control data sets, two schizopherenia
data sets by Hannon et al., and a rheumatoid arthritis data
set by Liu et al., all of which are expected to demonstrate
differences in blood cell composition between cases and
controls [26, 27]. In fact, in our analysis, we had an inher-
ently misspecified prior since we learned the prior from
hospital patients (outpatients), which are overall expected
to represent a sick population better than a more general
population. Specifically, out of the 595 individuals used
for learning the prior, 64% are known to have taken at
least one medication at the time of blood draw for cell
counting and 24% were admitted to the hospital due to
various conditions within 2 months before or after the
time of their blood draw (70.4% either were admitted or
took medications). We expect these conditions to be cor-
related with alterations in blood cell composition, and
therefore, the prior information we used is expected to
represent deviation from a healthy population and, as a
result, to misrepresent at least the control individuals in
the case/control data sets we analyzed.We further consid-
ered an additional fourth data set by Hannum et al., which
was originally studied in the context of aging (age range
19–101, mean 64.03, SD 14.73). Our prior was calculated
using sample with a different distribution of ages (range
20–88, mean 49.19, SD 16.69), thus potentially misrepre-
senting the cell composition distribution in the Hannum
et al. data to some extent.
Remarkably, we found the cell composition estimates
given by BayesCCE to effectively detect differences
between populations in the data sets, in spite of using
a single prior estimated from one particular popula-
tion. Specifically, we found that BayesCCE correctly
detected the cell types which differentiate between cases
and controls and between young and older populations;
notably, in some of the data sets, we found BayesCCE
to demonstrate some differences between cases and con-
trols which were not captured by the reference-based
estimates (Fig. 5). For example, NK cell abundance is
known to change in aging in a process known as NK
cell immunosenescence [28, 29], and monocyte levels are
known to increase in RA patients compared with healthy
individuals [30–32]. These differences in cell populations
were detected by BayesCCE but not by the reference-
based method, thus suggesting that BayesCCE could
uncover signal which was undetected by the reference-
based method (Fig. 5). That said, some other cell com-
position differences that were reported by BayesCCE but
not by the reference-based method or vice versa may be
the result of inaccuracies introduced by BayesCCE. Quan-
tifying more accurately and reliably to what extent each
method can detect cell composition differences would
require several large data sets with known cell counts.
In addition, for each data set, we estimated the distribu-
tion of white blood cells based on the BayesCCE cell count
estimates, and verified the ability of BayesCCE to correctly
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Fig. 5 The robustness of BayesCCE to prior misspecification and its ability to capture population-specific variability in cell-type composition, under
the assumption of six constituting cell types in blood (k = 6): granulocytes, monocytes, and four subtypes of lymphocytes (CD4+, CD8+, B cells, and
NK cells). Left side: t test results (presented by the negative log of the Bonferroni-adjusted p values) for the difference in proportions of each cell type
between cases and controls. Right side: the Dirichlet parameters of estimated cell counts stratified by cases and controls; red dashed rectangles
emphasize the high similarity in the estimated case/control-specific cell composition distributions yielded by the different methods, regardless of
the prior used (“prior”). Results are presented for four different data sets and using cell count estimates obtained by four approaches: the
reference-based method, BayesCCE, BayesCCE with known cell counts for 5% of the samples (BayesCCE imp), and BayesCCE with 5% additional
samples with both known cell counts and methylation from external data (BayesCCE imp ext). For the Hannum et al. data set, for the purpose of
presentation, cases were defined as individuals with age above the median age in the study. In the evaluation of BayesCCE imp and BayesCCE imp
ext, samples with assumed known cell counts were excluded before calculating p values and fitting the Dirichlet parameters
capture two distinct distributions (cases and controls or
young and older individuals), regardless of the single dis-
tribution encoded by the prior information (Fig. 5). While
BayesCCE provides one component per cell type, these
components are not necessarily appropriately scaled to
provide cell count estimates in absolute terms. Therefore,
for the latter analysis, we considered only the scenarios
in which cell counts are known for a small number of
individuals.
We further evaluated the scenario in which two differ-
ent population-specific prior distributions are available.
Specifically, one prior for cases and another one for con-
trols in the case/control studies, and one for young and
another one for older individuals in the aging study. For
the purpose of this experiment, we estimated the pri-
ors using the reference-based estimates of a subset of
the individuals (5% of the sample size) that were then
excluded from the rest of the analysis. Interestingly, we
found the inclusion of two prior distributions to provide
no clear improvement over using a single general prior
(Additional file 1: Table S3). Thus, further confirming the
robustness of BayesCCE to inaccuracies introduced by
the prior information due to cell composition differences
between populations.
Finally, we evaluated the effect of incorporating noisy
priors on the performance of BayesCCE by considering a
range of possible priors with different levels of inaccura-
cies, including a non-informative prior (Additional file 1:
Figure S9). Not surprisingly, we observed that given cell
counts for a small subset of samples, BayesCCE was over-
all robust to prior misspecification, which did not result
in a substantially reduced performance even given a non-
informative prior. In the absence of known cell counts,
the performance of BayesCCE was somewhat decreased,
however, remained reasonable even in the scenario of
a non-informative prior. Particularly, overall, BayesCCE
with a non-informative prior performed better than the
competing reference-free methods (ReFACTor, NNMF,
and MeDeCom). We attribute this result to the combi-
nation of the constraints defined in BayesCCE with the
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sparse low-rank assumption it takes, which seems to han-
dle more efficiently with the high-dimension nature of
the computational problem (see the “Methods” section).
We note that in the presence of a non-informative prior,
BayesCCE conceptually reduces to the performance of
ReFACTor, and therefore, it captures the same cell compo-
sition variability in the data. Yet, owing to the additional
constrains, BayesCCE allows to overcome ReFACTor in
capturing a set of components such that each component
corresponds to one cell type.
Discussion
We introduce BayesCCE, a Bayesian method for
estimating cell-type composition from heterogeneous
methylation data without the need for methylation ref-
erence. We show mathematically and empirically the
non-identifiability nature of the more straightforward
reference-free NNMF approach for inferring cell counts,
which tends to provide only linear combinations of the cell
counts. In contrast, while we do not provide conditions
for the uniqueness of a BayesCCE solution, our empirical
evidence from multiple data sets clearly demonstrates the
success of BayesCCE in providing desirable results of one
component per cell type by leveraging readily obtainable
prior information from previously collected data.
The parameters of the prior required by BayesCCE can
be estimated by utilizing previous studies that collected
cell counts from the tissue of interest. In our evaluation
of the method, we used whole-blood methylation data,
and we considered the classical definition of leukocyte cell
types, which relies on cell surface markers. Considering
other definitions of cell types is of potential interest; par-
ticularly, it would be interesting to examine to what extent
BayesCCE and the reference-free methods can capture
cell-type composition following a methylation-based defi-
nition of cell types (i.e., when defining cell types according
to their methylation patterns). Since BayesCCE captures
cell composition variation under the classical definition
of cell types by using the most dominant components
of variation in the data, the main cell types of a natural
methylation-based definition are expected to be a linear
combination of the cell types under the classical defini-
tion. Much like in the experiments we presented here,
wherein given a prior about the distribution of the cell
types BayesCCE directed the solution towards an appro-
priate linear transformation, we would expect BayesCCE
to perform similarly in the case of a methylation-based
definition of cell types (given appropriate prior informa-
tion about the distribution of cell types). Nevertheless,
obtaining such a definition and evaluating BayesCCE
under that definition would require obtaining appropri-
ate single cell methylation data, which is currently scarcely
available. Moreover, deriving an actual meaningful defini-
tion of cell types given such data is a non-trivial problem.
Therefore, until such definition and appropriate data are
available, we are bounded to consider the classical defini-
tion of cell types.
Since BayesCCE requires a prior which can be estimated
from previously collected cell counts without the need
for any other genomic data, obtaining such as prior is
relatively easy for many tissues, such as the brain [33],
heart [34], and adipose tissue [35]. Particularly, such data
should be substantially easier to obtain compared to refer-
ence data from sorted cells for the corresponding tissues.
Ideally, in order to learn the prior, one would want to
use cell counts coming from the same population as the
target population. Nevertheless, empirically, we observe
that BayesCCE leverages the prior to direct the solu-
tion while still allowing enough flexibility, which makes it
robust even to substantial deviations of the prior from the
true underlying cell composition distribution. In fact, our
results demonstrate that BayesCCE handles biases intro-
duced by the prior remarkably well. Particularly, it allows
to capture differences in cell compositions between dif-
ferent populations in the same study, thus providing an
opportunity to study cell composition differences between
different populations even in the absence of methylation
reference.
Since no large data sets with measured cell counts are
currently publicly available, we used a supervised method
[5] for obtaining cell-type proportion estimates, which
were used as the ground truth in our experiments. Even
though the method used for obtaining these estimates
was shown to reasonably estimate leukocyte cell pro-
portions from whole-blood methylation data in several
independent studies [18, 23, 24], these estimates may have
introduced biases into the analysis. Particularly, any inac-
curacies introduced by the reference-based method could
have directly affect the results of our evaluation. Our
results indicate that such inaccuracies are more likely in
some particular cell types over others. Failing to accu-
rately estimate a particular cell type may be the outcome
of various reasons. Notably, utilizing inappropriate refer-
ence data or failing to select a set of informative features
that mark a particular cell type may dramatically affect its
estimated values. Other reasons which are not method-
ological may also lead to inaccuracies of the estimates.
For example, two cell types with very similar methyla-
tion patterns will be hardly distinguishable. In spite of
the potential pitfalls of using estimates as a baseline for
evaluation, we believe that our results on several indepen-
dent data sets, including simulated data, and the use of
a prior estimated from a large data set of high-resolution
cell counts, provide a compelling evidence for the utility
of BayesCCE.
We further demonstrate that imputation of cell counts
can be highly accurate when cell counts are available for
some of the samples in the data. Particularly, based on
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our experiments, only as few as a couple of dozens of
samples with known cell counts are needed in order to
substantially improve performance. Moreover, in the gen-
eral setup of BayesCCE, where no cell counts are known,
each component corresponds to one cell type, however,
not necessarily in the right scale and there is no automatic
way to determine the identity of that cell type. In contrast,
in the case of cell count imputation, where cell counts are
known for a subset of the samples, the assignment of com-
ponents into cell types is straightforward. In addition, as
we showed, BayesCCE is able to reconstruct cell counts
up to a small absolute error (i.e., each component is scaled
to form cell proportion estimates of one particular known
cell type).
We note that in our evaluation of BayesCCE, we con-
sidered only whole-blood data sets. Studying other tissues
or biological conditions is clearly of interest. However, in
the absence of other tissue-specificmethylation references
that were clearly shown to allow obtaining reasonable
cell-type proportion estimates, evaluation of performance
based on tissues other than the whole blood will not
be reliable. We therefore opt to focus on evaluating the
performance of BayesCCE using multiple large whole-
blood data sets. Importantly, beyond its potential utility
for complex biological scenarios in which reference data
is unavailable, BayesCCE may also provide an oppor-
tunity to improve cell count estimates in whole-blood
studies in scenarios where the currently available refer-
ence data is not appropriate. Notably, in a recent work,
we have shown using multiple whole-blood data sets that
ReFACTor outperforms the reference-based method in
correcting for cell composition [19]. Differences in perfor-
mance between ReFACTor (upon which BayesCCE relies
for obtaining a starting point that captures the cell com-
position variation in the data) and the reference-based
method are expected to be especially large in studies
where the available reference data do not represent the
individuals in the study well. We argue that this is likely
to typically be the case, as the current go-to whole-blood
reference consists of only six individuals [11], which rep-
resent a very specific and narrow population in terms
of methylome altering factors, such as age [14], gender
[15, 16], and genetics [17]. That said, large data sets with
experimentally measured cell counts are required in order
to fully investigate and demonstrate these claims.
We further note that in our benchmarking of BayesCCE
with existing reference-free methods, we considered only
a subset of the available methods in the literature. Other
reference-free methods that have been suggested in the
context of accounting for cell composition in methylation
data exist; however, these do not provide explicit compo-
nents, but rather only implicitly account for cell compo-
sition variability in association studies. While in principle
these methods can be modified to produce components,
in this work, we focused only on methods that can be
readily used to provide explicit components for evalua-
tion. We further note that several supervised and unsu-
pervised decomposition methods have been suggested
for estimating cell composition from gene expression
[36–40]. However, these were refined for gene expression
data and, to the best of our knowledge, none of these
methods takes into account prior knowledge about the cell
composition distribution as in BayesCCE. It remains of
interest to investigate whether BayesCCE can be adapted
for estimating cell composition from gene expression
without the need for purified expression profiles.
Finally, our approach is based on finding a suitable lin-
ear transformation of the components found by ReFAC-
Tor [8]. It is therefore important to follow the guidelines
for the application of ReFACTor, such as incorporation
of methylation-altering covariates; these guidelines were
recently highlighted elsewhere [19, 41]. Since BayesCCE
relies on the ReFACTor components, it is limited by their
quality, and particularly, if the variability of some cell type
is not captured by ReFACTor, BayesCCE will not be able
to estimate that cell type well. Such a result is possible in
scenarios where the variation of a particular cell type is
substantially weaker than other sources of variation in the
data (which are unrelated to cell-type composition); we
note, however, that this potential limitation is not exclu-
sive for ReFACTor or BayesCCE but rather a general lim-
itation of all existing reference-free methods. BayesCCE
will effectively provide the same result as ReFACTor if
used for correcting for a potential cell-type composi-
tion confounder in methylation data. Since ReFACTor
does not allow to infer direct cell count estimates but
rather linear transformations of those, we suggest to use
BayesCCE in cases in which a study of individual cell
types is performed and therefore ReFACTor cannot be
used. In case merely a correction for cell composition is
desired, we suggest to use BayesCCE when cell counts are
known for a subset of the samples, and otherwise to use
ReFACTor.
Conclusion
We introduce a Bayesian method for estimating cell-type
composition from heterogeneous methylation data using
a prior on the cell composition distribution. In contrast to
previousmethods, using BayesCCE, we can generate com-
ponents such that each component corresponds to a single
cell type. These components can allow researchers to per-
form types of downstream analyses that are not possible
using previous reference-free methods, which essentially
capture linear combinations of several cell types in each
component they provide. Based on our results, showing
a further substantial improvement by incorporating some
cell counts into the analysis, we recommend that in future
studies either the cell counts be measured for at least a
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couple of dozens of the samples or the external data of
samples with measured cell counts be utilized.
Methods
Notations and related work
Let O ∈ Rm×n be an m sites by n sample matrix of DNA
methylation levels coming from a heterogeneous source
consisting k cell types. For methylation levels, we consider
what is commonly referred to as beta-normalized methy-
lation levels, which are defined for each sample in each
site as the proportion of methylated probes out of the total
number of probes. Put differently, Oji ∈[ 0, 1] for each site
j and sample i. We denote M ∈ Rm×k as the cell-type-
specific mean methylation levels for each site and denote
a row of this matrix, corresponding to the jth site, using
Mj,·. Additionally, we denote R ∈ Rn×k as the cell-type
proportions of the samples in the data. A common model
for observed mixtures of DNA methylation is
Oji = Mj,·RTi + ji (1)
ji ∼ N(0, σ 2) (2)
∀i∀h : Rih ≥ 0 (3)
∀i :
k∑
h=1
Rih = 1 (4)
∀j∀h : 0 ≤ Mjh ≤ 1 (5)
where the error term ji models measurement noise and
other possible unmodeled factors. The constraints in (3)
and in (4) require the cell proportions to be positive and
to sum up to one in each sample, and the constraints
in (5) require the cell-type-specific mean levels to be in
the range [ 0, 1]. This model was initially suggested for
DNA methylation in the context of reference-based esti-
mation of cell proportions by Houseman et al. [5]. We are
interested in estimating R. Taking a standard maximum
likelihood approach for fitting the model results in the
following optimization problem:
Rˆ, Mˆ = argmin
R,M
‖O − MRT‖2F (6)
s.t ∀i∀h : Rih ≥ 0 (7)
∀i :
k∑
h=1
Rih = 1 (8)
∀j∀h : 0 ≤ Mjh ≤ 1 (9)
where ‖·‖2F is the squared Frobenius norm. The reference-
based method [5] first obtains an estimate of M from
reference methylation data collected from sorted cells
of the cell types composing the studied tissue. Once an
estimate of M is fixed, R can be estimated by solving a
standard quadratic program.
If the matrix M is unknown, which is a reference-free
version of the problem, the above formulation of the
problem can be regarded as a version of non-negative
matrix factorization (NNMF) problem. NNMF has been
suggested in several applications in biology; notably,
the problem of inference of cell-type composition from
methylation data has been recently formulated as an
NNMF problem [9]. In order to optimize the model, the
authors used an alternating optimization procedure in
which M or R are optimized while the other is kept fixed.
However, as demonstrated by the authors [9], this solu-
tion results in the inference of a linear combination of the
cell proportions R. Put differently, more than one com-
ponent of the NNMF is required for explaining each cell
type in the data. This was recently further highlighted
and explained using geometric considerations [10], which
nicely showed the non-identifiable nature of the NNMF
model in (6) in case that a perfect factorization of O
into M,R exists (i.e., O = MRT ). However, in prac-
tice, perfect factorization never exists in real biological
data. Thus, in addition to empirical evidence from sev-
eral data sets on which we apply the NNMF method (see
the “Results” section), in the next subsection, we pro-
vide amathematical proof for the non-identifiability of the
NNMF model in (6) under a more general case, where a
perfect factorization does not necessarily exist.
In an attempt to overcome the non-identifiability of the
model in (6) and to provide cell-type proportions when
reference methylation data are not available, a recent
modification of theNNMFmodel has been suggested [10].
The method, MeDeCom, solves the optimization of the
NNMF model while including additional penalty term in
the objective function. Derived from biological knowl-
edge about mean methylation levels, the penalty nega-
tively weights mean methylation levels diverging from a
known bimodal behavior of methylation levels, wherein
CpGs tend to be overall methylated or unmethylated
[10]. While the modified objective suggested in MeDe-
Com overcomes the non-identifiability of the NNMF
model for a given weight of the penalty (λ), it is not
entirely clear how to select λ. To circumvent this prob-
lem, the authors proposed a cross-validation procedure
for the selection of λ. However, our empirical results from
four large whole-blood methylation data sets, as well as
from simulated data, show sub-optimal performance for
MeDeCom, similar to the solutions of the simpler NNMF
model. Our results suggest that the modification intro-
duced by MeDeCom may not effectively avoid the non-
identifiability nature of the NNMF model, possibly due
to insufficient prior information or inability to effectively
determine an appropriate value for λ.
Another recent reference-free method for estimating
cell composition in methylation data, ReFACTor [8], per-
forms an unsupervised feature selection step followed by
a principal components analysis (PCA). Similarly to the
NNMF solution, ReFACTor is an unsupervised method
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and it only finds principal components (PCs) that form
linear combinations of the cell proportions rather than
directly estimates the cell proportion values [8].
Non-identifiability of the NNMFmodel
We hereby show by construction the non-identifiability
nature of the NNMF model in (6). For this proof, instead
of the constraints in (9), we consider a slightly modified
version of the constraints:
∀j∀h : 0 < Mjh < 1 (10)
While in theory we may have an equality (i.e., Mjh = 0
or Mjh = 1), in practice, such sites are typically not mea-
sured or excluded from the analysis, since they would not
be demonstrating any variability.
Proposition 1 Let Rˆ, Mˆ be a solution to the prob-
lem in (6). There exist R˜ = Rˆ, M˜ = Mˆ such that∥∥∥O − MˆRˆT
∥∥∥
2
F
= ∥∥O − M˜R˜T∥∥2F and the constraints in (7),
(8), and (10) are satisfied.
Proof Let 0 < c < 1, define Q ∈ Rk×k to be the identity
matrix up to two entries: Q11 = 1 − c,Q12 = c. It fol-
lows thatQ−1 is also the identity matrix up to two entries:
Q−111 = 11−c ,Q−112 = cc−1 .
Denote R˜ = RˆQ and denote M˜ = Mˆ (Q−1)T , we get that
‖O−M˜R˜T‖2F = ‖O−Mˆ
(
Q−1
)T QTRˆT‖2F = ‖O−MˆRˆT‖2F
The constraints in (7) hold since R˜ih ≥ 0 for each 1 ≤ i ≤
n, 1 ≤ h ≤ k. The constraints in (8) hold since for each
1 ≤ i ≤ n
k∑
l=1
R˜il =
k∑
h=1
k∑
l=1
RˆilQlh
= (1 − c)Rˆi1 + cRˆi1 +
k∑
h=2
Rˆil =
k∑
h=1
Rˆil = 1
In addition, M˜Thj ∈ (0, 1) for 2 ≤ h ≤ k, 1 ≤ j ≤ m. In
order to completely satisfy the constraints in (10), we also
require these constraints to be satisfied for h = 1, 1 ≤ j ≤
m. It is easy to see that for each j the latter is satisfied if
0 < c < min
{
1−MˆT1j
1−MˆT2j
, Mˆ
T
1j
MˆT2j
}
Therefore, we can simply select a value of c in the range
0 < c < minj
{
min
{
1−MˆT1j
1−MˆT2j
, Mˆ
T
1j
MˆT2j
}}
Note that we necessarily have either
0 < c < minj
{
min
{
1−MˆT1j
1−MˆT2j
, Mˆ
T
1j
MˆT2j
}}
< 1
or
0 < c < minj
{
min
{
1−MˆT2j
1−MˆT1j
, Mˆ
T
2j
MˆT1j
}}
< 1
In the latter case, we can switch the positions of the first
two columns in M. Equality of the minimum to 1 in both
cases would mean thatM1 = M2, which would mean that
the problem is non-identifiable, as the first two cell types
cannot be distinguished in this scenario. As a result of the
above, the constraints in (10) can be satisfied for a range
of values of c. 
Model
We suggest a more detailed model by adding a prior on R
and taking into account potential covariates. Specifically,
we assume that
RTi ∼ Dirichlet(α1, ...,αk) (11)
where α1, ...,αk are assumed to be known. In practice,
the parameters are estimated from external data in which
cell-type proportions of the studied tissue are known.
Such experimentally obtained cell-type proportions were
used to test the appropriateness of the Dirichlet prior in
describing cell composition distribution (data not shown).
Also, we consider additional factors of variation affect-
ing observed methylation levels, in addition to variation
in cell-type composition. Specifically, denote X ∈ Rn×p
as a matrix of p covariates for each individual and S ∈
R
m×p as a matrix of corresponding effects of the p covari-
ates on each of the m sites. As before, we are interested
in estimating R, the cell-type proportions of the k cell
types. Deriving a maximum likelihood-based solution for
this model and repeating the constraints for completeness
result in the following optimization problem:
Rˆ, Mˆ, Sˆ = argmin
R,M,S
1
2σ 2
∥∥∥O − MRT − SXT
∥∥∥
2
F
−
k∑
h=1
(αh − 1)
n∑
i=1
log(Rih) (12)
s.t ∀i∀h : Rih ≥ 0 (13)
∀i :
k∑
h=1
Rih = 1 (14)
∀j∀h : 0 ≤ Mjh ≤ 1 (15)
Our intuition in this model is that since the priors on R
are estimated from real data, incorporating themwill push
the solution of the optimization to return estimates of R
which are closer to the true values as opposed to a linear
combination of them.
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Algorithm
Our algorithm uses ReFACTor as a starting point. Specif-
ically, we estimate R by finding an appropriate lin-
ear transformation of the ReFACTor principal compo-
nents (ReFACTor components). In principle, any of the
reference-free methods we examined (ReFACTor, NNMF,
and MeDeCom) could be used as the starting point for
our method. However, we found that ReFACTor captures
a larger portion of the cell composition variance compared
with the alternatives (Additional file 1: Figure S1).
Applying ReFACTor on our input matrix O, we get a list
of t sites that are expected to be most informative with
respect to the cell composition in O. Let O˜ ∈ Rt×n be a
truncated version of O containing only the t sites selected
by ReFACTor. We apply PCA on O˜ to get L ∈ Rt×d,P ∈
R
n×d , the loadings and scores of the first d ReFACTor
components. Then, we reformulate the original optimiza-
tion problem in terms of linear transformations of L and P
as follows:
Aˆ, Vˆ , Bˆ = argmin
A,V ,B
1
2σ 2
∣∣∣
∣∣∣O˜ − LAVTPT − LBXT
∣∣∣
∣∣∣
2
F
(16)
−
k∑
h=1
(αh − 1)
n∑
i=1
log
⎛
⎝
d∑
l=1
PilVlh
⎞
⎠
s.t ∀i∀h :
d∑
l=1
PilVlh ≥ 0 (17)
∀i :
k∑
h=1
d∑
l=1
PilVlh = 1 (18)
∀j∀k : 0 ≤
d∑
l=1
LjlAlh ≤ 1 (19)
where A ∈ Rd×k is a transformation matrix such that
M˜ = LA (M˜ being a truncated version ofM with the t sites
selected by ReFACTor), V ∈ Rd×k is a transformation
matrix such that R = PV , and B ∈ Rd×p is a transforma-
tionmatrix such that LB corresponds to the effects of each
covariate on the methylation levels in each site. The con-
straints in (17) and in (18) correspond to the constraints
in (13) and in (14), and the constraints in (19) correspond
to the constraints in (15).
Given Vˆ , we simply return Rˆ = PVˆ as the estimated
cell proportions. Note that in the new formulation we are
now required to learn only d(2k + p) parameters—d, k,
and p being small constants—a dramatically decreased
number of parameters compared with the original prob-
lem which requires nk + m(k + p) parameters. By taking
this approach, we make an assumption that O˜ consists of
a low-rank structure that captures the cell composition
using d orthogonal vectors. While a natural value for d
would be k, d is not bounded to be k. Particularly, in cases
where substantial additional cell composition signal is
expected to be captured by later ReFACTor components
(i.e., components beyond the first k), we would expect to
benefit from increasing d. Clearly, overly increasing d is
expected to result in overfitting and thus a decrease in
performance. Finally, taking into account covariates with
potentially dominant effects in the data should alleviate
the risk of introducing noise into Rˆ in case of mixed
low-rank structure of cell composition signal and other
unwanted variation in the data. We note, however, that
similar to the case of correlated explaining variables in
regression, considering covariates that are expected to be
correlated with the cell-type composition may result in
underestimation of A,V and therefore to a decrease in the
quality of Rˆ.
Imputing cell counts using a subset of samples with
measured cell counts
In practice, we observe that each of BayesCCE’s compo-
nents corresponds to a linear transformation of one cell
type rather than to an estimate of that cell type in absolute
terms. That is, it still lacks the right scaling (multiplication
by a constant and addition of a constant) for transform-
ing it into cell-type proportions. Furthermore, we would
like the ith BayesCCE component to correspond to the
ith cell type described by the prior using the αi parame-
ter. Empirically, this is not necessarily the case, especially
in scenarios where some of the αi values are similar. In
order to address these two caveats, we suggest incorpo-
rating measured cell counts for a subset of the samples in
the data.
Assume we have n0 reference samples in the data with
known cell counts R(0) and n1 samples with unknown cell
counts R(1) (n = n0+n1). This problem can be regarded as
an imputation problem, in which we aim at imputing cell
counts for samples with unknown cell counts. We can find
Mˆ by solving the problem in (12) under the constraints
in (15) for the n0 reference samples while replacing R with
R(0) and keeping it fixed. Then, given Mˆ, we can now solve
the problem in (16), after replacing LA with Mˆ (i.e., we
find only V ,B now), under the following constraints:
∀(1 ≤ i ≤ n0)∀h :
d∑
l=1
P(0)il Vlh = R(0)ih (20)
∀(1 ≤ i ≤ n1)∀h :
d∑
l=1
P(1)il Vlh ≥ 0 (21)
∀(1 ≤ i ≤ n1) :
k∑
h=1
d∑
l=1
P(1)il Vlh = 1 (22)
where P(0) contains n0 rows corresponding to the refer-
ence samples in P and P(1) contains n1 rows correspond-
ing to the remaining samples in P. In this case, both
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problems of estimating M and solving (16) while keep-
ing Mˆ fixed are convex—the first problem takes the form
of a standard quadratic problem and the latter results in
an optimization problem of the sum of two convex terms
under linear constraints. Using Mˆ, estimated from cell
counts and corresponding methylation levels of a group of
samples, and adding the constraints in (20) are expected to
direct the inference of R towards a set of components such
that each one corresponds to one known cell type with a
proper scale.
We note that given an estimate Mˆ as described above,
we can also solve directly the problem in (12) rather than
the problem in (16). This approach may be more desired
in cases where P does not effectively capture the cell
composition variation in the data. In the context of our
study, however, it is not possible to reliably evaluate the
approach of solving directly the problem in (12), owing
to the fact that the ground truth we set for evaluation is
based on the same matrixM. Specifically, in this case, the
cell proportions of the reference individuals are expected
to recover the same matrix M that was used for com-
puting the ground truth proportions of the non-reference
individuals. As a result, the estimated proportions of the
non-reference individuals will be exactly the ground truth
that is used in the evaluation (up to a statistical error
arising from the estimation of M), regardless of the true
accuracy of the estimate Mˆ with respect to the true M
and regardless of the true accuracy of the cell proportion
estimates.
Implementation and practical issues
We estimate σ 2 in (16) as the mean squared error of pre-
dicting O˜with P and X. The α1, ...,αk Dirichlet parameters
of the prior can be estimated from cell counts using max-
imum likelihood estimators. In practice, we add a column
of ones to both L and P in (16) in order to assure feasi-
bility of the problem—these constant columns are used to
compose the meanmethylation level per site across all cell
types and the mean cell proportion fraction in each cell
type across all samples. In addition, we slightly relax some
of the constraints in the problem to avoid problems due to
numeric instability and inconsistent noise issues. First, the
inequality constraints in (17) and in (21) are changed to
require the cell proportions to be greater than  > 0, as a
result of the logarithm term in the objective ( = 0.0001).
In addition, we do not impose the equality constraints
in (18) and in (22) but rather allow a small deviation from
equality (5%), and given cell counts for a subset of the
samples, we allow a small deviation from the equality con-
straints in (20) due to expected inaccuracies of cell count
measurements (1%). The last two constraints are required
for assuring a feasible solution, owing to the fact that we
fit Mˆ, Rˆ jointly. Specifically, since the starting point for the
optimization is essentially a set of principal components
(given by ReFACTor), which are not guaranteed to capture
only cell composition variation, in practice, obtaining lin-
ear transformations that precisely satisfy the constraints
is expected to be an exception rather than the rule. We
verified this empirically (data not shown), and we further
observed that these relaxations eventually result in feasi-
ble solutions which typically tend to tightly concentrate
around the original constraints.
We performed all the experiments in this paper using
a Matlab implementation of BayesCCE. Specifically, we
solved the optimization problems in BayesCCE using the
fmincon function with the default interior-point algo-
rithm, and we used the fastfit [42] Matlab package for
calculating maximum likelihood estimates of the Dirich-
let priors. All executions of BayesCCE required less than
an hour (and typically several minutes) on a 64-bit Mac
OS X computer with 3.1 GHz and 16 GB of RAM.
Corresponding code is available at https://github.com/
cozygene/bayescce.
Evaluation of performance
The fraction of cell composition variation
(
R2
)
captured
by each of the reference-free methods, ReFACTor, NNMF,
and MeDeCom, was computed for each cell type using a
linear predictor fitted with the first k components pro-
vided by each method. In order to evaluate the perfor-
mance of BayesCCE, for each component i, we calculated
its absolute correlation with the ith cell type and reported
the mean absolute correlation (MAC) across the k esti-
mated cell types. While the Dirichlet prior assigns a spe-
cific parameter αh for each cell type h, empirically, we
observed that in the case of k = 6 with no known cell
counts for a subset of the samples, the ith BayesCCE com-
ponent did not necessarily correspond to the ith cell type.
Put differently, the labels of the k cell types had to be
permuted before calculating the MAC. In this case, we
considered the permutation of the labels which resulted
with the highest MAC as the correct permutation. In the
rest of the cases, we did not apply such permutation (all
the experiments using k = 3 and all the experiments
using k = 6 with known cell counts for a subset of the
samples).
For evaluating ReFACTor, NNMF, and MeDeCom,
reference-free methods which do not attribute their com-
ponents to specific cell types in any scenario, we consid-
ered for each method the permutation of its components
leading to the highest MAC in all experiments when com-
pared with BayesCCE. In addition, we considered the
absolute error of the estimates from the ground truth as an
additional quality measurement. We calculated the mean
absolute error (MAE) across the k estimated cell types.
When calculating absolute errors for the ReFACTor com-
ponents, we scaled each ReFACTor component to be in
the range [ 0, 1].
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Implementation and application of the reference-free and
reference-based methods
We calculated the ReFACTor components for each data
set using the parameters k = 6 and t = 500 and according
to the default implementation and recommended guide-
lines of ReFACTor as described in the GLINT tool [41]
and in a recent work [19], while accounting for known
covariates in each data set. More specifically, in the
Hannum et al. data [20], we accounted for age, sex, ethnic-
ity, and batch information; in the Liu et al. data [21], we
accounted for age, sex, smoking status, and batch infor-
mation; and in the two Hannon et al. data sets [22], we
accounted for age, sex, and case/control state. We used
the first six ReFACTor components (d = 6) for simulated
data in order to accommodate with the number of simu-
lated cell types, and the first ten components (d = 10) for
real data, as real data are typically more complex and are
therefore more likely to contain substantial signal in latter
components.
The NNMF components were computed for each data
set using the default setup of the RefFreeEWAS R pack-
age from the subset of 10,000 most variable sites in the
data set, as performed in the NNMF paper by the authors
[9]. Similarly, the MeDeCom components were computed
for each data set using the default setup of the MeDeCom
R package [10] from the subset of 10,000 most variable
sites in the data set, as repeatedly running the method on
the entire set of CpGs was revealed to be computationally
prohibitive. The regularization parameter λ was selected
according to a minimum cross-validation error criterion,
as instructed in the MeDeCom package.
We used the GLINT tool [41] for estimating blood cell-
type proportions for each one of the data sets, according
to the Houseman et al. method [5], using 300 highly infor-
mative methylation sites defined in a recent study [24] and
using reference data collected from sorted blood cells [11].
Data sets
We evaluated the performance of BayesCCE using a total
of six data sets, as described below. For the real data exper-
iments, we downloaded four publicly available Illumina
450K DNA methylation array data sets from the Gene
Expression Omnibus (GEO) database: a data set by Han-
num et al. (accession GSE40279) from a study of aging
rate [20], a data set by Liu et al. (accession GSE42861)
from a recent association study of DNA methylation with
rheumatoid arthritis [21], and two data sets by Hannon et
al. (accessions GSE80417 and GSE84727; denote Hannon
et al. I and Hannon et al. II) from a recent association
study of DNA methylation with schizophrenia.
We preprocessed the data according to a recently
suggested normalization pipeline [43]. Specifically, we
retrieved and processed raw IDAT methylation files using
R and the minfi R package [44] as follows. We removed
65 single nucleotide polymorphism (SNP) markers and
applied the Illumina background correction to all inten-
sity values, while separately analyzing probes coming from
autosomal and non-autosomal chromosomes. We used
a detection p value threshold of p value < 10−16 for
intensity values, setting probes with p values higher than
this threshold to be missing values. Based on these miss-
ing values, we excluded samples with call rates < 95%.
Since IDAT files were not made available for the Hannum
et al. data set, we used the methylation intensity levels
published by the authors.
As for data normalization, following the same suggested
pipeline [43], we performed a quantile normalization of
the methylation intensity values, subdivided by probe
type, probe sub-type, and color channel. Beta-normalized
methylation levels were eventually calculated based on
intensity levels (according to the recommendation by Illu-
mina). On top of that, we excluded probes with over
10% missing values and used the “impute” R package for
imputing remaining missing values. Additionally, using
GLINT [41], we excluded from each data set all CpGs
coming from the non-autosomal chromosomes, as well as
polymorphic and cross-reactive sites, as was previously
suggested [45].
We further removed outlier samples and samples with
missing covariates. In more details, we removed six sam-
ples from theHannum et al. data set and two samples from
the Liu et al. data set, which demonstrated extreme values
in their first two principal components (over four empir-
ical standard deviations). Furthermore, we removed from
the Liu et al. data set two additional remaining samples
that were regarded as outliers in the original study of Liu
et al., and we removed from the Hannon et al. data sets
samples with missing age information. The final numbers
of samples remained for analysis were n = 650, n = 658,
n = 638, and n = 656, and the numbers of CpGs remained
were 382,158, 376,021, 381,338, and 382,158, for the Han-
num et al. data set, Liu et al. data set, and the Hannon et al.
I and Hannon et al. II data sets, respectively.
For learning prior information about the distribution
of blood cell-type proportions, we used electronic medi-
cal record (EMR)-based study data that were acquired via
the previously published Department of Anesthesiology
and Perioperative Medicine at UCLA’s perioperative data
warehouse (PDW) [46]. The PDW is a structured report-
ing schema that contains all the relevant clinical data
entered into an EMR via the use of Clarity, the relational
database created by EPIC (EPIC Systems, Verona, WI) for
data analytics and reporting. We used high-resolution cell
count measurements from adult individuals (n = 595)
for fitting a Dirichlet distribution. The resulted param-
eters of the prior were 15.0727, 1.8439, 2.5392, 1.7934,
0.7240, and 0.7404 for granulocytes, monocytes, CD4+,
CD8+, B cells, and NK cells, respectively. The parameters
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of the prior calculated for the case of three assumed cell
types (k = 3) were 7.7681, 0.9503, and 2.9876 for granulo-
cytes, monocytes, and lymphocytes, respectively. Finally,
for generating simulated data sets and for generating cor-
relation maps of cell-type-specific methylomes, we used
publicly available data of methylation reference of sorted
cell types collected in six individuals from whole-blood
tissue (GEO accession GSE35069) [11].
Data simulation
We simulated data following a model that was previously
described in details elsewhere [8]. Briefly, we used methy-
lation levels from sorted blood cells [11] and, assum-
ing normality, estimated maximum likelihood parameters
for each site in each cell type. Cell-type-specific DNA
methylation data were then generated for each simulated
individual from normal distributions with the estimated
parameters, conditional on the range [0,1], for six cell
types and for each site. Cell proportions for each individ-
ual were generated using a Dirichlet distribution with the
same parameters used in the real data analysis. Eventually,
observed DNA methylation levels were composed from
the cell-type-specific methylation levels and cell propor-
tions for each individual, and a random normal noise was
added to every data entry to simulate technical noise (σ =
0.01). To simulate inaccuracies of the prior, the Dirichlet
parameters required by BayesCCE were learned from cell-
type proportions of 50 samples generated at random from
a Dirichlet distribution using the parameters learned from
real data.
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